Luke Timmerman
Showing 1–2 of 2 transcripts.
- Milken Institute58 min
Young Entrepreneurs Who Are Rewriting the Biopharma Business Model
Luke Timmerman, Elizabeth Iorns, Ethan Perlstein, D.A. Wallach, Alice Zhang
In response to stagnant R&D productivity despite rapid technological advancement, a coalition of entrepreneurs including Prolara's Ethan Perlstein, Science Exchange's Elizabeth, and Verge Genomics' Alice is deploying novel business models to accelerate drug discovery. These initiatives leverage CRISPR, data science, and patient-led capital to bypass traditional inefficiencies, aiming to fail early and validate molecular hypotheses faster than legacy pharmaceutical methods allow. The panel further advocates for structural reforms in academia and big pharma to integrate computational and biological expertise, ultimately seeking to transform biotech from a chemistry-based discipline into a software-driven engineering field.
- Milken Institute1h 1m
Biotech: Bull Market or Bubble?
Luke Timmerman, Alex Denner, Bob Hugin, Annalisa Jenkins, John Reed
Panelists from major pharmaceutical firms and investment firms analyzed the biotech sector's transition from a 2012–2015 valuation bubble to a value-driven correction that prioritizes clinical utility over speculative hype. Industry leaders emphasized that while technological convergence in genomics and personalized medicine drives innovation, the sector faces critical challenges in pricing models, R&D efficiency, and patient trial enrollment that threaten long-term profitability. Consensus among the executives suggests that future success depends on collaborative regulatory frameworks, demonstrable patient outcomes, and new manufacturing efficiencies to justify the billions required for drug development.